+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation



A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation



New England Journal of Medicine 325(5): 311-315



Background: The use of nicotine chewing gum combined with psychological support improves the success rate in quitting smoking. We studied the safety and efficacy of a transdermal nicotine patch in smoking cessation. Mehtod: The conducted a double-blind randomized study comparing the effects of a 16-hour nicotine patch (15 .+-. 3.5 mg of nicotine in 16 hours) with those of a placebo patch. Of the 289 smokers (207 women and 82 men) enrolled in the study, 145 were treated with nicotine patches and 144 with placebo patches for 16 weeks. Results. Rates of sustained abstinence were significantly better with active treatment than with placebo: 53, 41, 24, and 17 percent of those in the nicotine-patch group were abstinent after 6, 12, 26, and 52 weeks, respectively, as compared with 17, 10, 5, and 4 percent of those in the placebo-patch group (P < 0.0001). Only two subjects with the nicotine patch and one with the placebo patch had to withdraw from the study because of side effects. Conclusions: The nicotine skin patch proved to be safe and effective, as demonstrated by a higher rate of abstinence than with placebo. However, the absolute rate of abstinence after one year was only 17 percent, which is lower than the rate in studies that have combined the use of nicotine chewing gum with behavioral therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039060935

Download citation: RISBibTeXText

PMID: 2057036

DOI: 10.1056/nejm199108013250503


Related references

Effectiveness of a transdermal nicotine patch in smoking cessation a double blind randomized placebo controlled trial. Clinical Research 39(4): 887A, 1991

A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience 263(1): 75-82, 2013

Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. Journal of the Formosan Medical Association 97(8): 547-551, 1998

Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Archives of Internal Medicine 160(20): 3128-3134, 2000

Sociodemographic and smoking behavioral predictors associated with smoking cessation according to follow-up periods: a randomized, double-blind, placebo-controlled trial of transdermal nicotine patches. Journal of Korean Medical Science 22(6): 1065-1070, 2007

Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet. Respiratory Medicine 3(2): 131-138, 2015

Double-blind placebo controlled trial of dextrose tablets and nicotine patch in smoking cessation. Psychopharmacology. 136(2): 201-204, Ch, 1998

An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. Addiction 110(6): 1027-1034, 2015

Trial of transdermal nicotine patch in smoking cessation. Journal of the Medical Association of Thailand 78(9): 466-468, 1995

Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy. American Journal on Addictions 13(5): 438-446, 2005

A randomized trial of smoking cessation using the nicotine transdermal patch in inner-city African Americans. Jgim 10(4 Suppl ): 38, 1995

Nicotine-replacement therapy with use of a transdermal nicotine patch--a randomized double-blind placebo-controlled trial. Mayo Clinic Proceedings 65(12): 1529-1537, 1990

Nicotine dependence, psychological distress and personality traits as possible predictors of smoking cessation. Results of a double-blind study with nicotine patch. Addictive Behaviors 34(1): 28-35, 2009

Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment with nicotine patch and cognitive behavioral treatment Final report. Drug & Alcohol Dependence 66(Suppl. 1): S47, 2002

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 63(8): 717-724, 2008